The numbers don't lie, but they do omit. Capital B, a European Bitcoin treasury company, just closed a €21 million private placement. The headline says they're buying 270 more Bitcoin. The fine print says existing shareholders could lose 24.1% of their per-share Bitcoin exposure. The market is treating this as a non-event. That's the first mistake.
I've spent the last decade dissecting financial structures that look benign on the surface and rot from the inside. This one has a familiar stench. The warrants aren't a footnote. They're the story.
The Setup: A Follower in a Leader's Game
Capital B operates in the Bitcoin treasury niche, a model pioneered and perfected by MicroStrategy. Michael Saylor turned MSTR into a leveraged Bitcoin play using convertible notes — debt that converts to equity at a premium, diluting only when the stock performs. It's elegant. It's been tested across a full market cycle.
Capital B is not MicroStrategy. It's a smaller European player with 3,145 BTC in the treasury, set to rise to 3,415 BTC after this placement settles on August 31st. The company is copying the playbook but swapping the instrument. Instead of convertibles, they're using units with attached warrants — four warrants per share, with strike prices at €0.75, €0.98, and €1.27, exercisable over five years. The placement price is €0.58 per unit.
Let that sink in. The warrants are priced 29% to 119% above the current placement. That's not a vote of confidence. That's a bet on a specific price trajectory that may never materialize.
The Core Teardown: Dilution Math That Cuts Both Ways
I ran the numbers through my own model, cross-checking the company's disclosed figures. The immediate placement is nearly neutral. Per million shares, BTC exposure drops from 7.4725 to 7.4711 — a negligible 0.02% decline. That's the number the company wants you to see.
Here's what they're not leading with: if all warrants are exercised, per-million-share BTC drops to 5.6730. That's a 24.1% reduction. A quarter of your Bitcoin exposure, gone, not through market volatility but through structural dilution.
The company's own disclosure admits this. It's buried in the footnotes, but it's there. What's not there is any accounting for the older BSA-series warrants, the warrants attached to convertible bonds, or the €300 million TOBAM facility that remains unissued. The disclosed dilution is incomplete. The real number is likely worse.
This is where my forensic instincts kick in. When a company discloses dilution but excludes multiple categories of dilutive instruments, that's not an oversight. That's a choice. The question is whether it's a choice driven by regulatory compliance or by narrative protection.
The Structural Flaw: Equity Financing for a Bitcoin Bull Thesis
Let me be precise about what Capital B is doing. They're selling equity to buy Bitcoin. The value proposition is simple: Bitcoin appreciates faster than the dilution cost. In a bull market, this works. The stock rises, the warrants stay out of the money, and everyone's happy.
But this model has a critical vulnerability that MSTR's convertible structure doesn't share. Convertibles only dilute when the stock price exceeds the conversion price — when shareholders are already winning. Warrants, by contrast, are a contingent liability from day one. They sit on the cap table like a loaded gun, waiting for a price trigger that may or may not come.
If Bitcoin enters a bear market, Capital B's stock will fall. The warrants will expire worthless, which sounds good for existing shareholders until you realize the company won't get the follow-on capital it needs to buy more Bitcoin. The financing loop breaks. The narrative collapses.
I've seen this pattern before. In 2022, I stress-tested two L2 solutions that promised theoretical TPS numbers they couldn't deliver under real-world conditions. The gap between the pitch deck and the execution was a chasm. Capital B has the same gap, just in a different domain. The pitch is "Bitcoin exposure through a regulated vehicle." The execution is "dilution with extra steps."
The Governance Red Flag: Blank Checks and Silent Shareholders
Here's the detail that should concern every current shareholder: in June, shareholders authorized €5 billion in capital increases and a €100 billion credit facility. For a company with roughly €30 million in Bitcoin holdings, that's not a war chest. That's a blank check.
Management now has the authority to dilute shareholders on a scale that dwarfs this €21 million placement. The current offering is just the opening move. The warrants are the second move. What comes after is anyone's guess, but the authorization suggests management is thinking in terms of aggressive, repeated dilution to fund Bitcoin accumulation.
This is the "dilution spiral" risk. Each financing round buys Bitcoin, but each round also reduces per-share BTC exposure. If Bitcoin's appreciation doesn't outpace the dilution rate, shareholders lose on both sides — the asset underperforms and their claim on it shrinks.
The Contrarian View: What the Bulls Get Right
I'm not here to bury Capital B entirely. The bulls have a point, and it's worth acknowledging.
First, the immediate placement is genuinely neutral. The 0.02% dilution is noise. Anyone selling on this news alone is overreacting.
Second, the Bitcoin treasury model has real merit. MSTR's success proves there's institutional demand for Bitcoin exposure through traditional equity markets. Capital B is positioning for that demand in Europe, where the competitive landscape is thinner. Metaplanet has Japan. Boyaa has Asia. Capital B could carve out Europe.
Third, the warrant structure, while dilutive, is also a potential source of future capital. If the stock performs, the warrants get exercised, and the company gets fresh funds to buy more Bitcoin. The strike prices are high, but they're not impossible. A sustained bull run could make them look prescient.
The problem is that all three of these points depend on Bitcoin going up. The model has no hedge, no downside protection, and no alternative strategy. It's a leveraged bet on a single asset, wrapped in a corporate structure that charges you for the privilege of making it.
The Information Asymmetry: What You're Not Being Told
The most troubling aspect of this deal isn't the dilution itself. It's the incomplete disclosure. The company's dilution calculations exclude the BSA-series warrants, the convertible bond warrants, and the TOBAM facility. That's not a minor omission. That's a material gap in the information needed to assess the true risk.
In my due diligence work, I've learned to treat incomplete disclosures as red flags. When a company shows you a partial picture, the missing pieces are usually the ones that hurt. The question isn't whether the full picture is worse than what's shown. It's how much worse.
I'd estimate the true potential dilution, including all disclosed and undisclosed instruments, could push the per-share BTC reduction to 30% or more. That's a material difference from the 24.1% headline number.
The Market Context: Timing a High-Water Mark
This placement is happening at a specific moment in the Bitcoin cycle. Prices are elevated. Sentiment is greedy. The Bitcoin treasury narrative is in its acceleration phase, riding on MSTR's coattails.
That's precisely when dilution risk is most dangerous. Capital B is raising funds near what could be a local top, buying Bitcoin at current prices, and hoping appreciation covers the dilution cost. If Bitcoin corrects 30% — a normal correction in this asset class — the company's entire thesis breaks. The stock falls, the warrants go underwater, and the next financing round becomes impossible.
I've audited enough projects to know that the best time to raise capital is when you don't need it. Capital B is raising because they need it, and the market is pricing that urgency into the warrant structure.
The Signal in the Silence
Metadata whispers what the contract screams. In this case, the silence is in the disclosure footnotes. The absence of BSA-series details. The missing TOBAM terms. The unquantified convertible bond warrants. These aren't oversights. They're choices.
Silence in the logs is louder than any statement. When a company is selective about what it discloses, it's telling you what it doesn't want you to know. The question is whether you're listening.
The Takeaway: Diligence Is Boredom Executed Perfectly
This deal isn't a disaster. It's a warning. Capital B is a small player in a niche market, copying a proven model with a structurally inferior instrument. The warrants create a 24.1% dilution overhang that the market hasn't priced in. The incomplete disclosure suggests the real number is higher.
For current shareholders: demand full disclosure of all dilutive instruments. Calculate your true per-share BTC exposure. Don't rely on the company's numbers.
For potential investors: compare Capital B's structure to MSTR's convertibles. The difference is the cost of your Bitcoin exposure. It's not trivial.
For the broader market: this is a case study in how Bitcoin treasury companies can destroy shareholder value while appearing to accumulate Bitcoin. The narrative says "we're buying Bitcoin." The math says "you're being diluted."
The image is static. The provenance is a phantom. The warrants are the reality.
I'll be watching the warrant exercise announcements over the next five years. So should you. The first sign of trouble won't be a price crash. It'll be a footnote in a quarterly report, quietly revealing that the dilution was worse than anyone calculated.
That's how these stories always end. Not with a bang, but with a disclosure.